glp 1 drugs and alcohol consumption GLP-1 Weight Loss Alcohol: Why Ozempic Reduces Both GLP-1 Medications and Drinking: Why

Sternkopf et al., 2020

Juhl Christian, R

The molecule and safety profile are identical

And they can achieve a slow, gradual weight loss, usually over the course of two years, potentially more, and then be seen for weight maintenance

Cardiovascular Outcomes Liraglutide (LEADER trial): 13% reduction in major adverse cardiovascular events (MACE) in patients with Type 2 diabetes and high cardiovascular risk Statistically significant cardiovascular protection Semaglutide (SELECT trial): 20% reduction in MACE in patients with obesity and established cardiovascular disease Studied specifically for cardiovascular outcomes in obesity (not just diabetes) Both medications provide cardiovascular protection, but semaglutides evidence is more recent, more robust, and specifically applicable to patients with obesity regardless of diabetes status